Mitomycin C, a bioreductive alkylating agent with clinical utility against several human tumors, was found to be selectively toxic at a relatively low concentration (1.5 micro M) to EMT6 tumor cells made chronically hypoxic by preincubation in 95% N2-5% CO2 for 4 hr prior to drug exposure. This selective cytotoxicity correlated well with the preferential activation and metabolism of mitomycin C...

Solid neoplasms may contain deficient or poorly functional vascular beds, a property that leads to the formation of hypoxic tumor cells, which form a therapeutically resistant cell population within the tumor that is difficult to eradicate by ionizing irradiation and most existing chemotherapeutic agents. As an approach to the therapeutic attack of hypoxic cells, we have measured the cytotoxici...

BACKGROUND Mitomycin C has recently been used to prevent nasal synechiae and sinus ostium stenosis after endoscopic sinus surgery. OBJECTIVE OF REVIEW To compare nasal synechiae rate between topical Mitomycin C and saline or no treatment. TYPE OF REVIEW Systematic review and meta-analysis. DATA SOURCES MEDLINE, SCOPUS, and Cochrane Register of Controlled Trials databases were used to iden...

The unpredictable clinical toxicity observed in patients treated with mitomycin C and the observation that this agent must be reduced to an active form before alkylating target molecules have led to the development of a bioassay which is capable of detecting biologically active forms of mitomycin C in the plasma of drug-treated patients. The bioassay makes use of a repairdeficient mutant of Chi...

purpose: to compare outcomes and recurrence rates of amniotic membrane transplantation (amt) plus intraoperative mitomycin c (mmc) and conjunctival rotational autograft (cra) plus intraoperative mmc in pterygium surgery methods: ninety-two eyes of 92 patients with primary nasal pterygium were enrolled. all patients were randomized to undergo either amt or cra. forty-three patients underwent amt...